The Gut Microbiome as a Biomarker and Therapeutic Target of Immune Checkpoint Inhibitors: A Review for Oncologists
Cells · 12.11.2025 · 14 (22) · 1779
DOI: 10.3390/cells14221779 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cells, online erschienen am 12.11.2025. Verfasst von Thiti Susiriwatananont und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology, Department of Medicine, Faculty of Medicine, Chulalongkorn University and The King Chulalongkorn Memorial Hospital, Ban…. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome, Immune Checkpoint Inhibitors, Oncologists, Neoplasms. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 182 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Immune checkpoint inhibitors (ICIs) have transformed cancer therapy, yet their benefits remain limited to a subset of patients, underscoring the need for more reliable biomarkers and novel therapeutic strategies. The gut microbiome has emerged as a critical modulator of systemic immunity and a promising determinant of ICI response. Evidence links specific microbial features, taxa, and bioactive metabolites to enhanced antitumor immunity, whereas disruptions, such as antibiotic exposure, are associated with poorer outcomes. Advances in sequencing and multi-omics technologies have provided more profound insights into microbiome-immune crosstalk, though methodological heterogeneity continues to challenge reproducibility. Translational studies demonstrate that microbiome-based intervention, including fecal microbiota transplantation (FMT), biotics supplementation, and engineered microbial strains, can enhance ICI efficacy or mitigate immune-related toxicities. Despite encouraging early clinical signals, broader implementation requires methodological rigor, standardized protocols, and innovative trial designs that account for host and environmental factors. For clinicians, the most immediate strategies involve prudent antibiotic stewardship and patient enrollment in microbiome-focused clinical trials. Overall, the gut microbiome is a promising biomarker and a therapeutic target, representing a new frontier for personalizing immunotherapy and improving patient outcomes in oncology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Medical Oncology, Department of Medicine, Faculty of Medicine, Chulalongkorn University and The King Chulalongkorn Memorial Hospital, Bangkok 10330, Thailand.
- Jacoby Center for Breast Health, Division of Hematology and Medical Oncology, Mayo Clinic, Jacksonville, FL 32224, USA.
- Department of Medicine, Faculty of Medicine, Thammasat University Hospital, Pathum Thani 12120, Thailand.
- Inflammatory Bowel Disease Center, Division of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, FL 32224, USA.
- Pendulum Therapeutics, Inc., San Francisco, CA 94110, USA.
ORCID-Profile: Thiti Susiriwatananont, Maria Vazquez Roque, Adam Perlman
Zitieren
APA
Susiriwatananont, T., Eiamprapaporn, P., Vazquez Roque, M., Farraye, F. A., Perlman, A., & Chumsri, S. (2025). The Gut Microbiome as a Biomarker and Therapeutic Target of Immune Checkpoint Inhibitors: A Review for Oncologists. Cells, 14(22), 1779. https://doi.org/10.3390/cells14221779
Vancouver
Susiriwatananont T, Eiamprapaporn P, Vazquez Roque M, Farraye FA, Perlman A, Chumsri S. The Gut Microbiome as a Biomarker and Therapeutic Target of Immune Checkpoint Inhibitors: A Review for Oncologists. Cells. 2025;14(22):1779. doi:10.3390/cells14221779
BibTeX
@article{Susiriwatananont2025,
author = {Susiriwatananont, Thiti and Eiamprapaporn, Panuch and Vazquez Roque, Maria and Farraye, Francis A and Perlman, Adam and Chumsri, Saranya},
title = {The Gut Microbiome as a Biomarker and Therapeutic Target of Immune Checkpoint Inhibitors: A Review for Oncologists},
journal = {Cells},
year = {2025},
volume = {14},
number = {22},
pages = {1779},
doi = {10.3390/cells14221779}
}
EUVIMED